Quarterly Updates15 May 2026, 02:55 pm
Alembic Pharma Q4 FY26: Revenue up 4%, Net Profit up 29% YoY
AI Summary
Alembic Pharmaceuticals Ltd reported its consolidated financial results for Q4 FY26. Revenue from operations increased by 4% YoY to ₹1,848 Cr. Profit After Tax stood at ₹203 Cr, up 29% YoY. EBITDA pre R&D increased by 8% YoY to ₹455 Cr. The company launched its US branded business with Pivya. India Branded Business delivered 4% YoY growth, reaching ₹568 Cr. US Formulation grew by 11% to ₹564 Cr.
Key Highlights
- Revenue from operations increased by 4% YoY to ₹1,848 Cr in Q4 FY26.
- Profit After Tax increased by 29% YoY to ₹203 Cr.
- US Formulation grew by 11% to ₹564 Cr during the quarter.
- Alembic launched its US branded business with Pivya.
- India Branded Business grew by 4% YoY, reaching ₹568 Cr.